Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “hold” rating reissued by Credit Suisse Group in a report released on Monday. They currently have a $81.00 price objective on the biotechnology company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 2.40% from the company’s current price.
Other equities research analysts have also recently issued reports about the company. HC Wainwright lifted their target price on Sarepta Therapeutics from $75.00 to $92.00 and gave the stock a “buy” rating in a research note on Monday. Piper Jaffray Companies reiterated an “overweight” rating and set a $76.12 target price (down from $83.00) on shares of Sarepta Therapeutics in a research note on Monday. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 10th. Zacks Investment Research cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Finally, UBS Group reiterated an “outperform” rating and set a $56.51 target price (down from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $70.55.
Sarepta Therapeutics (NASDAQ SRPT) traded up $4.74 during midday trading on Monday, hitting $79.10. The stock had a trading volume of 2,785,699 shares, compared to its average volume of 1,460,000. The company has a market cap of $5,110.00, a PE ratio of -98.88 and a beta of 1.51. Sarepta Therapeutics has a 12 month low of $28.14 and a 12 month high of $80.23. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54.
Hedge funds have recently bought and sold shares of the business. Hall Laurie J Trustee grew its holdings in Sarepta Therapeutics by 2,430.8% during the 4th quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 3,160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sarepta Therapeutics by 39.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares in the last quarter. Prentiss Smith & Co. Inc. purchased a new position in Sarepta Therapeutics during the 4th quarter valued at about $199,000. Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the 4th quarter valued at about $217,000. Finally, Aperio Group LLC purchased a new position in Sarepta Therapeutics during the 4th quarter valued at about $219,000. 85.14% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics (SRPT) Stock Rating Reaffirmed by Credit Suisse Group” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/12/sarepta-therapeutics-srpt-stock-rating-reaffirmed-by-credit-suisse-group.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.